Literature DB >> 22023411

Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience.

Natlada Limotai1, Genko Oyama, Criscely Go, Oscar Bernal, Tiara Ong, Sarah J Moum, Roongroj Bhidayasiri, Kelly D Foote, Dawn Bowers, Herbert Ward, Michael S Okun.   

Abstract

OBJECTIVE: Characterize potential risk factors and the relationship of dopamine agonist (DA) withdrawal syndrome (DAWS), dopamine dysregulation syndrome (DDS), and impulse control disorders (ICDs) in Parkinson's disease (PD).
METHODS: A retrospective chart review categorized cases into three groups: DAWS, DDS, and ICDs.
RESULTS: A total of 1,040 subjects met inclusion criteria. There were 332 subjects with a history of tapering DAs and 26 (7.8%) developed DAWS. Fourteen (1.3%) and 89 (8.6%) met the criteria for both DDS and ICD. Subjects with DAWS, DDS, and ICDs had a higher baseline dose of DA, levodopa, and total dopaminergic medication (p < .05), compared to those without the three conditions. DDS was found to be related to the DAWS group (p < .001). When comparing to the PD population without DDS, younger age at onset of PD (p = .027), presence of DAWS (p < .001), ICDs (p = .003), and punding (p = .042) were all correlated with the DDS group, while male sex (p = .045), younger age at onset of PD (p < .001), presence of DAWS (p < .001), and presence of DDS (p = .001) and punding (p < .001) were related to the ICD group.
CONCLUSIONS: There was a strong relationship between DAWS, DDS, and ICD in this large PD cohort. Dopaminergic therapy in a subset of PD patients was strongly associated with addiction-like behavioral issues.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22023411     DOI: 10.3109/00207454.2011.633722

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  10 in total

1.  A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease.

Authors:  Kallol Ray Chaudhuri; Antoniya Todorova; Melissa J Nirenberg; Miriam Parry; Anne Martin; Pablo Martinez-Martin; Alexandra Rizos; Tove Henriksen; Wolfgang Jost; Alexander Storch; Georg Ebersbach; Heinz Reichmann; Per Odin; Angelo Antonini
Journal:  Mov Disord Clin Pract       Date:  2015-03-16

Review 2.  Drug deprescription-withdrawal risk, prevention, and treatment.

Authors:  Madison K Bangert; Gabriel M Aisenberg
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-12-20

3.  Prospective cohort study of impulse control disorders in Parkinson's disease.

Authors:  Jesse Bastiaens; Benjamin J Dorfman; Paul J Christos; Melissa J Nirenberg
Journal:  Mov Disord       Date:  2013-01-02       Impact factor: 10.338

Review 4.  Dopamine agonist withdrawal syndrome: implications for patient care.

Authors:  Melissa J Nirenberg
Journal:  Drugs Aging       Date:  2013-08       Impact factor: 3.923

5.  Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.

Authors:  Ashok Sriram; Herbert E Ward; Anhar Hassan; Sanjay Iyer; Kelly D Foote; Ramon L Rodriguez; Nikolaus R McFarland; Michael S Okun
Journal:  J Neurol       Date:  2012-09-25       Impact factor: 4.849

6.  Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug.

Authors:  Jin Mizushima; Keisuke Takahata; Noriko Kawashima; Motoichiro Kato
Journal:  Ann Gen Psychiatry       Date:  2012-07-07       Impact factor: 3.455

Review 7.  Impulsive and compulsive behaviors in Parkinson's disease.

Authors:  Guoxin Zhang; Zhentao Zhang; Ling Liu; Jiaolong Yang; Jinsha Huang; Nian Xiong; Tao Wang
Journal:  Front Aging Neurosci       Date:  2014-11-14       Impact factor: 5.750

8.  Dopamine agonist withdrawal syndrome associated factors: A retrospective chart review.

Authors:  Xiomara Garcia; Mohammad Edrees Mohammad; Shnehal Patel; Xin Xin Yu; Hubert H Fernandez
Journal:  Clin Park Relat Disord       Date:  2022-07-16

Review 9.  Risk factors of impulsive-compulsive behaviors in PD patients: a meta-analysis.

Authors:  Lanxiao Cao; Tian Xu; Gaohua Zhao; Dayao Lv; Jinyu Lu; Guohua Zhao
Journal:  J Neurol       Date:  2021-08-09       Impact factor: 4.849

Review 10.  Dopamine Agonists and Impulse Control Disorders: A Complex Association.

Authors:  Marie Grall-Bronnec; Caroline Victorri-Vigneau; Yann Donnio; Juliette Leboucher; Morgane Rousselet; Elsa Thiabaud; Nicolas Zreika; Pascal Derkinderen; Gaëlle Challet-Bouju
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.